Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

This study tests a combination of two drugs — irinotecan liposome and S-1 (an oral chemotherapy) — for people with nasopharyngeal carcinoma (a cancer at the back of the nose) that has returned or spread and no longer responds to immunotherapy drugs called PD-1/L1 inhibitors. **You may be eligible if...** - You are 18 or older with confirmed nasopharyngeal carcinoma - Your cancer returned or spread after receiving at least one immunotherapy-based treatment (anti-PD-1/L1) - Your cancer cannot be cured with surgery or radiation - You have at least one measurable tumor on scans - You are generally well enough to carry out daily activities - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your cancer has not previously been treated with immunotherapy - You have serious organ dysfunction - You have certain active infections or other cancers Talk to your doctor to see if this trial is right for you.